Dietary supplements, nutraceutical compositions, medical foods, animal feeds, and pharmaceutical compositions for treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. A synergistic composition containing a high dose range of agmatine and acceptable salts thereof and in combination with other active ingredients having salutary effects in treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. The composition prepared with excipients and compatible carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solution to facilitate consumption.

Dietary supplements, nutraceutical compositions, medical foods, animal feeds, and pharmaceutical compositions for treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. A synergistic composition containing a high dose range of agmatine and acceptable salts thereof and in combination with other active ingredients having salutary effects in treating osteoarthritis and other osteo-articular conditions involving neuropathy and associated symptoms. The composition prepared with excipients and compatible carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solution to facilitate consumption.

Mucolytic agents for use in treating pulmonary sarcoidosis are described herein. Patients in need of treatment for pulmonary sarcoidosis are administered a therapeutically effective amount of a mucolytic agent such as DNase I, Mesna or DiMesna. In some embodiments, the DNase I is a recombinant human DNase I such as dornase alfa.

The present disclosure relates to methods for preventing, treating and/or reducing the severity of conditions or diseases associated with coronavirus infections. The methods comprise of administering an effective amount of a pharmaceutically acceptable compound which is an antioxidant or a substance capable of increasing the level of glutathione in the body. Preferably, the compound is a glutathione precursor selected from cysteine or a derivative thereof, cystine or a derivative thereof, methylsulfonylmethane (MSM) and dimethyl sulfoxide (DMSO), in particular, the glutathione precursor is N-acetylcysteine (NAC). In some embodiments, the compound is selected from lipoic acid, glycine, glutamate, or a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

The present disclosure relates to methods for preventing, treating and/or reducing the severity of conditions or diseases associated with coronavirus infections. The methods comprise of administering an effective amount of a pharmaceutically acceptable compound which is an antioxidant or a substance capable of increasing the level of glutathione in the body. Preferably, the compound is a glutathione precursor selected from cysteine or a derivative thereof, cystine or a derivative thereof, methylsulfonylmethane (MSM) and dimethyl sulfoxide (DMSO), in particular, the glutathione precursor is N-acetylcysteine (NAC). In some embodiments, the compound is selected from lipoic acid, glycine, glutamate, or a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.

An applicator can include a dispenser for dispensing an amount of a therapeutic composition, which can include an amount of sugar or sugar alcohol and an amount of an alkalizing agent. In some cases, the alkalizing agent can include L-Arginine. In some cases, 75% or more of the composition by weight has a comedogenicity rating of 3 or less on a scale of 0-5. The dispenser can also have a power supply configured to provide power through a contact tip of the dispenser to provide nerve stimulation, such as using vibration, heating, cooling, and/or electrical stimulation.

An applicator can include a dispenser for dispensing an amount of a therapeutic composition, which can include an amount of sugar or sugar alcohol and an amount of an alkalizing agent. In some cases, the alkalizing agent can include L-Arginine. In some cases, 75% or more of the composition by weight has a comedogenicity rating of 3 or less on a scale of 0-5. The dispenser can also have a power supply configured to provide power through a contact tip of the dispenser to provide nerve stimulation, such as using vibration, heating, cooling, and/or electrical stimulation.

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders.

A technique is provided for suppressing the crystal precipitation of an aqueous composition containing a halogenated isoquinoline derivative during low-temperature preservation. An aqueous composition comprising a compound represented by Formula (1):

##STR00001## wherein x represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and brimonidine or a salt thereof.

A technique is provided for suppressing the crystal precipitation of an aqueous composition containing a halogenated isoquinoline derivative during low-temperature preservation. An aqueous composition comprising a compound represented by Formula (1):

##STR00001## wherein x represents a halogen atom, or a salt thereof, or a solvate of the compound or the salt thereof, and brimonidine or a salt thereof.